Teva Pharmaceutical Industries (NYSE:TEVA) Trading 2.5% Higher - Should You Buy?

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report)'s stock price rose 2.5% during mid-day trading on Monday . The company traded as high as $15.48 and last traded at $15.46. Approximately 5,546,124 shares changed hands during trading, a decline of 42% from the average daily volume of 9,641,032 shares. The stock had previously closed at $15.08.

Analyst Ratings Changes

Several brokerages recently commented on TEVA. Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Thursday, March 27th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Performance

The firm has a fifty day moving average of $16.67 and a 200 day moving average of $18.04. The stock has a market cap of $16.83 billion, a price-to-earnings ratio of -10.24, a PEG ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently made changes to their positions in the company. FMR LLC grew its position in Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the period. Duquesne Family Office LLC lifted its stake in shares of Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after purchasing an additional 7,569,450 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Teva Pharmaceutical Industries by 7,945.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock worth $86,350,000 after purchasing an additional 4,732,374 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after purchasing an additional 4,418,961 shares during the last quarter. Finally, Todd Asset Management LLC purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at about $58,243,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.